Figure 1 **Varlitinib 400mg BID + Cisplatin/Capecitabine-78 year-old male**




Figure 2 Varlitinib 400mg BID + Cispaltin/Capecitabine-46 year-old female





Figure 3 Valitinib 400mg BID + Cispaltin/Capecitabine-56 year-old male






Figure 4 Varlitinib 500mg BID + Cispaltin/Capecitabine-60 year-old male

Figure 5 Varlitinib 300mg BID + Oxaliplatin/ Capecitabine




Figure 6a Varlitinib Phase Ib-TAIWAN




Figure 6b Varlitinib Phase Ib-SINGAPORE




Figure 7a Change in Target Lesion Over Time –TAIWAN (as of June 2016)




Figure 7b Change in Target Lesion Over Time –Phase Ib SINGAPORE






Figure 8a Maximal % Change in Tumor Size from Baseline –TAIWAN (as of 20 June 2016)



- All patients received 300-500mg varlitinib and combined chemotherapy

#2A101 is CCA without target lesion, and had best response as SD (non-measurable lesion)
*2B102-0001 has target lesion reduction to 41% at C4. However, new lesion developed, thus the overall RECIST response is PD.

Figure 8b Maximal % Change in Tumor Size from Baseline –SINGAPORE



- All patients received 300-400mg ASLAN001 and doublet chemotherapy.
- Most patients had received at least 2 prior treatments, including XELOX, XELIRI, Gem/Cis, Herceptin etc.
- Not all patients have completed 4 cycles of therapy.
- 13 patients: 3 PR, 8 SD, 2 PD (23% response rate, 85% disease control)

Figure 9 Phase 2A/B Breast Cancer Study with Valitinib and Capecitabine or Lapatinib and Capecitabine- Change in Lesion Size Over 12 Weeks




Figure 10 Phase 2A/B Breast Cancer Study with Valitinib and Capecitabine or Lapatinib and Capecitabine-Waterfall Plot of Best Responses of Evaluable Subjects (RECIST % data, cut off date: 17 June 2016, n=29)




Figure 11 Phase 2A/B Breast Cancer Study with Varlitinib and Capecitabine or Lapatinib and Capecitabine- Best Responses All Subjects –Changes in Target Lesion Size Over Time




Figure 12 Days on Therapy (SINGAPORE)




Figure 13 Varlitinib IB/2A NeoAdjuvant Breast Cancer

